| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/02/2001 | EP1095026A1 Pharmaceutical agents |
| 05/02/2001 | EP1095021A1 Quinoline derivatives |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095018A1 Aminoiminoquinone and aminoquinone alkaloid compounds as caspase inhibitors |
| 05/02/2001 | EP1095016A1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095015A2 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |
| 05/02/2001 | EP1095003A1 Cytokine production and tyrosine kinase inhibitors |
| 05/02/2001 | EP1094863A2 Methods for treating neurological injuries and disorders |
| 05/02/2001 | EP1094830A1 USE OF COMPOSITION COMPRISING AT LEAST ONE SUBSTANCE WITHIN THE GROUP GnRH-ANALOGUES FOR TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD) |
| 05/02/2001 | EP1094828A1 Use of neglected target tissue antigens in modulation of immune responses |
| 05/02/2001 | EP1094826A1 Novel therapeutic agents that modulate alpha-1a adrenergic receptors |
| 05/02/2001 | EP1094817A1 Compositions comprising gaba analogs and caffeine |
| 05/02/2001 | EP1094816A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 05/02/2001 | EP1094810A1 Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric g protein membrane fixation |
| 05/02/2001 | EP1094804A2 The treatment of renal colic with gaba analogs |
| 05/02/2001 | EP1094803A2 Use of gaba-analogues for treating insomia |
| 05/02/2001 | EP1094712A1 Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics |
| 05/02/2001 | EP1006801A4 Sertoli cells as neurorecovery inducing cells for neurodegenerative disorders |
| 05/02/2001 | EP0984959A4 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| 05/02/2001 | EP0983257A4 Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| 05/02/2001 | EP0973392A4 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/02/2001 | EP0885218B1 Oxa- and thia-diazole muscarinic receptor antagonists |
| 05/02/2001 | EP0778820B1 Neurotrophic and antiproliferative compounds |
| 05/02/2001 | EP0769947B1 Indolinone compounds for the treatment of disease |
| 05/02/2001 | EP0743853B1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 05/02/2001 | CN1293673A 1-(3-heteroarylpropyl-or-prop-2-enyl)-4-benzylpiperidines used as NMDA receptor antagonists |
| 05/02/2001 | CN1293669A Benzylpiperazingl-and benzylipeeridinyl ethanone derivatives, their preparation method and their use as dopamine D receptor antagonists |
| 05/02/2001 | CN1293666A Benzenesulfonamide-derivatives and their use as medicaments |
| 05/02/2001 | CN1293665A New compounds and their use as positive AMPA receptor modulators |
| 05/02/2001 | CN1293655A Bicyclo [2.2.1] heptanes and related compounds |
| 05/02/2001 | CN1293573A Methods of treating tardive dyskinesia and other movement disorders |
| 05/02/2001 | CN1293571A Extended release tiagabine formulations with reduced side-effects |
| 05/02/2001 | CN1293569A New treatments for nervous disorders |
| 05/02/2001 | CN1293195A New polycyclicazaindole compound, its preparation method are medicine composition containing same |
| 05/02/2001 | CN1293193A Preparation of piperidyl amino methyl trifluoro methyl cyclo other compounds |
| 05/02/2001 | CN1293053A Medicine for treating facial paralysis and its preparing process |
| 05/02/2001 | CN1293052A Health-care tea for tranquilizing and improving sleep |
| 05/02/2001 | CN1065135C Medicine for curing encephalatrophy and preparation thereof |
| 05/01/2001 | US6225448 1gG /transferrin receptor fusion protein |
| 05/01/2001 | US6225444 Bind calcium and which are useful in treating stroke and other neurodegenerative diseases |
| 05/01/2001 | US6225354 Subjecting unsaponified beeswax to liquid extraction with liquid organic extractant in which primary aliphatic alcohols are soluble; recovering alcohol mixture and isolating alcohols |
| 05/01/2001 | US6225343 Compositions and methods comprising morphine gluconate |
| 05/01/2001 | US6225335 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease |
| 05/01/2001 | US6225331 For therapy and prophylaxis nasal congestion, otitis media, and sinusitis, treating cough, chronic obstructive pulmonary disease (copd) and/or asthma, benign prostatic hypertrophy, cardiovascular disorders, glaucoma, hyperemia, conjunctivitis |
| 05/01/2001 | US6225324 Antidepressant heterocyclic compounds |
| 05/01/2001 | US6225320 Treatment of pain, inflammation, migraine, emesis and posttherpetic neuralgia |
| 05/01/2001 | US6225316 3-phenyl-pyridine-derivatives |
| 05/01/2001 | US6225312 Piperazine and piperidine compounds |
| 05/01/2001 | US6225288 Implicated in modulating apoptosis; treatment of:cardiac and cerebral ischemia/reperfusion injury, spinal cord injury and organ damage during transplantation, chronic neurodegenerative diseases, immunodeficiency, diabetes, alopecia, aging |
| 05/01/2001 | US6225117 Antibodies against human IL-12 |
| 05/01/2001 | US6225057 Duplications of human chromosome 15q24-25 and anxiety disorders, diagnostic methods for their detection |
| 05/01/2001 | US6224875 Tanacetum parthenium extract and method of obtaining same |
| 05/01/2001 | US6224857 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics |
| 05/01/2001 | US6224849 Alkylaminobenzothiazole and-benzoxazole derivatives |
| 05/01/2001 | CA2197178C Bicyclolactam compounds, use of the same and intermediate in the production of the same |
| 05/01/2001 | CA2186919C Therapeutic anti-inflammatory and analgesic pharmaceutical composition containing nimesulide 4-nitro, 2 phenoxyphenyl methane sulphonamide for use transdermally and a process for the manufacture thereof |
| 04/26/2001 | WO2001029564A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 04/26/2001 | WO2001029563A1 Method of screening for inhibitors of asp2 |
| 04/26/2001 | WO2001029256A2 Cephalic pain susceptibility marker |
| 04/26/2001 | WO2001029255A2 Diagnostic test for cephalic pain |
| 04/26/2001 | WO2001029206A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 04/26/2001 | WO2001029178A2 Epo primary response gene 1, eprg1 |
| 04/26/2001 | WO2001029084A2 Novel human proteins and polynucleotides encoding the same |
| 04/26/2001 | WO2001029070A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 04/26/2001 | WO2001029067A1 Tetrapeptide stimulating functional activity of neurones, pharmacological agent based thereon and method of use thereof |
| 04/26/2001 | WO2001029055A2 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| 04/26/2001 | WO2001029049A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 04/26/2001 | WO2001029046A2 A salt of morphine |
| 04/26/2001 | WO2001029042A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 04/26/2001 | WO2001029039A1 Synthesis and methods of use of 9-substituted guanine derivatives |
| 04/26/2001 | WO2001029036A2 Allosteric sites on muscarinic receptors |
| 04/26/2001 | WO2001029034A1 Quinuclidine acrylamides |
| 04/26/2001 | WO2001029031A1 Process for the preparation of paroxetine |
| 04/26/2001 | WO2001029030A1 N-substituted 1-(lactone) isoquinolones for treating nervous disorders |
| 04/26/2001 | WO2001029029A1 Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists |
| 04/26/2001 | WO2001029028A1 9- (piperazinylalkyl) carbazoles as bax-modulators |
| 04/26/2001 | WO2001029026A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 04/26/2001 | WO2001029023A1 Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them |
| 04/26/2001 | WO2001029022A1 Benzopyran derivatives |
| 04/26/2001 | WO2001029017A2 N-SUBSTITUTED 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES AND 1,4-THIOBUTYROLACTONES FOR USE AS PROMOTER OF η-AMINOBUTYRIC ACID ACTIVITY AND FOR TREATING NERVOUS DISORDERS AND PREPARATION METHOD |
| 04/26/2001 | WO2001029015A2 Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists |
| 04/26/2001 | WO2001029012A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029011A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029008A1 Pyrazole derivatives which modulate human serotonin receptors |
| 04/26/2001 | WO2001029007A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 04/26/2001 | WO2001028978A1 Bicyclic amino acids as pharmaceutical agents |
| 04/26/2001 | WO2001028591A2 Injection vehicle for polymer-based formulations |
| 04/26/2001 | WO2001028578A2 A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME |
| 04/26/2001 | WO2001028574A2 Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| 04/26/2001 | WO2001028557A1 Cannabimimetic indole derivatives |
| 04/26/2001 | WO2001028546A1 Inhibition of amyloidoses by using aromatic or heteroaromatic compounds substituted by electron-withdrawing groups |
| 04/26/2001 | WO2001028545A2 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 04/26/2001 | WO2001028540A2 Agent for treating cephalic pain |
| 04/26/2001 | WO2001028539A2 Agent for treating cephalic pain |
| 04/26/2001 | WO2001028531A1 Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin |
| 04/26/2001 | WO2001028523A1 Powder pharmaceutical formulations |
| 04/26/2001 | WO2001028516A2 Sustained-release formulations for treating cns-mediated disorders |
| 04/26/2001 | WO2001028498A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 04/26/2001 | WO2001028497A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 04/26/2001 | WO2001028491A2 Method and composition for the treatment of dermatologic diseases |